Studies have shown that neoadjuvant nivolumab may provide long-term benefits for people with non-small cell lung cancer.

Published Date: 17 Feb 2023

BACKGROUND: NSCLC is the most common and important cause of cancer worldwide. Assessment: The patient...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Don't Call It Cancer; Clues to 'Exceptional' Responses; More Predictions for 2025

2.

Tipiracil hydrochloride and trifluridine tablets are approved by the USFDA for Natco Pharma.

3.

In a randomized trial, the kinder, gentler regimen for classical Hodgkin wins out.

4.

Chromatin organization linked to p53 tumor suppression mechanism

5.

Emerging ADC-Based Strategies in mNSCLC: Interpreting Clinical Evidence and Implications for Practice


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot